Crispr Therapeutics Correlations
| CRSP Stock | USD 51.25 1.02 2.03% |
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Crispr Therapeutics Correlation With Market
Average diversification
The correlation between Crispr Therapeutics AG and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Crispr Stock
Moving against Crispr Stock
| 0.43 | KO | Coca Cola Aggressive Push | PairCorr |
| 0.38 | DD | Dupont De Nemours | PairCorr |
| 0.38 | TRV | The Travelers Companies | PairCorr |
| 0.35 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.34 | VZ | Verizon Communications | PairCorr |
| 0.33 | XOM | Exxon Mobil Corp | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Crispr Stock performing well and Crispr Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Crispr Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AXXDF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| HTOCF | 0.09 | 0.04 | 0.00 | 2.87 | 0.00 | 0.00 | 1.52 | |||
| MTGRY | 1.56 | 0.09 | 0.00 | (0.10) | 0.00 | 5.12 | 42.78 | |||
| EPTI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BLSFY | 1.72 | 0.07 | 0.01 | (0.32) | 2.44 | 4.05 | 16.11 | |||
| BLX | 0.91 | (0.05) | 0.00 | (0.05) | 0.00 | 1.75 | 8.66 | |||
| TOKSF | 0.05 | 0.01 | 0.00 | 2.89 | 0.00 | 0.00 | 1.63 | |||
| TATLY | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Crispr Therapeutics Corporate Management
| Samarth Kulkarni | Chief Business Officer | Profile | |
| James JD | General Secretary | Profile | |
| Susan Kim | Vice Relations | Profile | |
| Craig Mello | Scientific Member | Profile | |
| Lawrence Klein | Chief Officer | Profile | |
| Chad Cowan | Scientific Founder | Profile |